A bone marrow transplant process co-developed by investigators at the Johns Hopkins Kimmel Cancer Center is safe and curative for adults with sickle cell disease, according to results of a trial completed at Johns Hopkins and about 20 additional cancer centers nationwide and in London. The treatment, available at multiple U.S. medical centers, is a viable and less costly alternative to recently approved gene therapy products for sickle cell disease, the authors say.
